CD33 CAR expressing NK-92 cells showed no significant adverse side effects in a phase 1 trial for the treatment of acute myeloid leukaemia (AML) (NCT02944162) [93] (Table 1). This evidence concerns the gene CD33 and acute myeloid leukemia.